Janux Therapeutics, Inc. (JANX)
| Market Cap | 837.92M |
| Revenue (ttm) | 380,000 |
| Net Income (ttm) | -7.66M |
| Shares Out | 36.10M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 23 |
| Last Price | $23.21 |
| Previous Close | $22.04 |
| Change ($) | 1.17 |
| Change (%) | 5.31% |
| Day's Open | 22.30 |
| Day's Range | 21.44 - 23.40 |
| Day's Volume | 153,391 |
| 52-Week Range | 16.32 - 37.99 |
LA JOLLA, Calif.--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the closing of its previo...
The 37th biotech to hit the public markets this year has a potentially $1 billion deal with Merck & Co. Inc. ( MRK , Financial).
Janux Therapeutics, Inc. (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the pricing of its initial public offering of 11,400,000 shares of its comm...
Janux Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
About JANX
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on our proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Our initial focus is on developing a novel class of T cell engagers (TCEs), an emerging class of immunotherapies that bridge a tumor cell and a T cell, to activate and redirect T cells to attack and eliminate tumors, and our lead product candidates are designed to target clinically validated drug targets. We are d... [Read more...]
| Industry Biotechnology | IPO Date Jun 11, 2021 |
| CEO David Campbell, Ph.D. | Employees 16 |
| Stock Exchange NASDAQ | Ticker Symbol JANX |